Aptar Digital Health Partners with Enable Injections to Develop Companion Digital Solution for enFuse® On-Body Delivery System
核心洞察
Aptar Digital Health (搜索) has been named as Enable Injections (搜索)' preferred digital health partner for the enFuse® On-Body Delivery System (搜索), designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration.
The companion digital solution will feature treatment data recording, onboarding modules, injection guidance, and patient-reported outcomes tracking to enhance patient experience and support adherence programs.
The modular digital platform will capture adherence data and patient outcomes remotely, providing analytics dashboards for pharmaceutical partners to support clinical development and real-world use.
Aptar Digital Health (搜索), a global leader in digital health solutions, has announced a strategic partnership with Enable Injections (搜索), Inc., naming Aptar as the preferred digital health partner for Enable's enFuse® On-Body Delivery System (搜索). The collaboration aims to develop a companion digital solution designed to guide patients and caregivers throughout the injection process and support engagement before, during, and after administration.
Digital Solution Features and Capabilities
The companion digital solution will be designed to enhance the patient experience and support adherence-related programs for the enFuse® system. Key features of the solution include treatment data recording, onboarding and training modules, injection guidance, patient-reported outcomes and symptom tracking. These components are intended to empower patients and caregivers with greater confidence and control over the treatment process.
Built on a flexible and scalable architecture, the digital solution will be deployed alongside the enFuse® system, enabling pharmaceutical partners to extend the value of their therapies beyond delivery. The platform is designed to evolve across the drug development lifecycle, supporting use cases from clinical trials through commercialization, aligned with development and launch strategies.
Data Analytics and Real-World Insights
Adherence data and patient reported outcomes will be captured remotely, securely stored and made available through analytics dashboards that generate actionable insights. These insights are intended to support clinical development, launch readiness and real-world use. The modular, program-specific design will allow pharmaceutical partners to integrate digital components into their clinical or commercial programs based on their specific needs.
By combining device-generated data with patient reported insights, the digital solution aims to help drive more informed decisions grounded in real-world usage patterns and patient experiences.
Industry Leadership Perspectives
"This collaboration seeks to enhance the treatment experience of patients beyond the moment of injection," said Michael D. Hooven, Chairman and CEO of Enable Injections (搜索). "Together, we will combine innovative drug delivery with digital support tools. This can help patients remain engaged in their therapy and enable healthcare providers to better understand and support each patient's journey."
Damien McKeon, SVP Strategic Partnerships at Aptar Digital Health (搜索), emphasized the clinical significance of the partnership: "Large-volume biologic therapies (搜索) are increasingly used to treat complex chronic conditions (搜索). They often require long-term adherence to achieve optimal outcomes. Digital solutions supporting treatment tracking and patient engagement can help address common adherence challenges associated with self-administration."
About the enFuse® System
The enFuse® On-Body Delivery System (搜索) is an innovative wearable technology designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration. The system aims to improve convenience, support improved outcomes, and advance healthcare system economics. Enable Injections (搜索) is currently working with multiple pharmaceutical partners to conduct clinical trials and plan for joint commercial launches of their therapies in combination with the enFuse® technology.